The effects of adipocytokines on the endocrino-metabolic features and obstetric outcome in pregnant obese women with polycystic ovary syndrome

被引:14
|
作者
Elkholi, Dina [1 ]
Nagy, Halah [2 ]
机构
[1] Tanta Univ, Fac Med, Dept Obstet & Gynecol, Tanta, Egypt
[2] Tanta Univ, Fac Med, Dept Clin Pathol, Tanta, Egypt
关键词
Polycystic ovary syndrome; Pregnancy outcome; Android obesity; Gynoid obesity; Adipocytokines;
D O I
10.1016/j.mefs.2014.02.001
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: To estimate the effects of adipocytokines on the metabolic and endocrine features, and the obstetric outcome in pregnant women with polycystic ovary syndrome (PCOS). Design: Prospective cross sectional study. Main outcome measures: plasma concentration of adipocytokines, insulin resistance/hyperinsulinism (IR/HI), lipid profile, androgens and obstetric outcome. Materials and methods: The study included hundred pregnant PCOS (PPCOS) women with android obesity (group 1), 100 pregnant non-PCOS women with android obesity (group 2), 100 PPCOS women with gynoid obesity (group 3), and 100 pregnant non-PCOS women with gynoid obesity (group 4). All patients in the four groups were primigravidae and women with PCOS (groups 1 and 3) became pregnant after treatment with clomiphene citrate and/or gonadotropins. Plasma concentrations of fasting glucose, fasting serum insulin, insulin sensitivity by quantitative insulin sensitivity check index (QUICKI), serum concentrations of triglycerides (TGs), total cholesterol (TC), high density lipoprotein cholesterol, (HDL-c), low density lipoprotein cholesterol (LDL-c); plasma adipocytokines: interleukin (IL)-10, adiponectin (both are insulin sensitizers and anti-inflammatory), pro-inflammatory cytokines: IL-6, prothrombin activator inhibitor-1(PAI-1), high sensitivity C-reactive protein (hsCRP); serum total testosterone (TT), sex-hormone binding globulin (SHBG), free androgen index (FAI) were estimated for the four groups between 22 and 24 weeks' gestation Glucose loading test was done at 22-24 weeks' gestation to check for gestational diabetes mellitus and if normal it was repeated at 30-34 weeks. Gestational hypertension (GH), preeclampsia (PE) and preterm labor (PTL) (delivery < 37 weeks' gestation) were recorded. Results: Groups 1 and 2 with android obesity had IR/HI, (QUICKI < 0.331 +/- 0.010). Groups 3 and 4 with gynoid obesity had normal insulin sensitivity (NIS), (QUICKI > 0.331 +/- 0.010). Serum concentration of TGs, LDL-c, and plasma concentration of IL-6, PAI-1, hsCRP were significantly higher in groups 1 and 2 than groups 3 and 4. Serum HDL-c, plasma IL-10 and adiponectin were significantly higher in groups 3 and 4 than groups 1 and 2. Serum TT and FAI were significantly higher in groups 1 and 3 (cases of PPCOS) than their controls. There was no significant difference in the serum concentration of TC between the four groups. Incidence of spontaneous early miscarriage (SM) in groups 1, 2, 3, and 4 was 36%, 12%, 33%, and 11% respectively. Incidence of SM was significantly higher in PPCOS than non-PCOS pregnancy irrespective of the type of obesity. Rate of late pregnancy complications, GDM, GH, PE and PTL was significantly higher in groups 1 and 2 with android obesity than groups 3 and 4 with gynoid obesity. There was no significant difference in the rates of cesarean section (CS) between the 4 groups. The rates of neonatal complications and perinatal mortality were significantly higher in groups 1 and 2 (android obesity) than groups 3 and 4 (gynoid obesity). Conclusion: TT and FAI were significantly higher in PPCOS with android obesity than PPCOS with gynoid obesity. Incidence of early SM (9-12 weeks) was significantly higher in PPCOS than in non-PCOS pregnancy irrespective of the type of obesity. Incidence of late-onset pregnancy complications, GDM, GH, PE and PTL was significantly higher in patients with android obesity than patients with gynoid obesity. PCOS per se seemed to be not related to the incidence of late-onset pregnancy complications. Pregnant patients with android obesity, (both PCOS and non-PCOS) with diminished serum concentration of anti-inflammatory cytokines, and increased serum concentration of pro-inflammatory cytokines had IR/HI and dyslipidemia. Pregnant patients with gynoid obesity, (both PCOS and non-PCOS) with normal serum concentration of anti-and pro-inflammatory cytokines had NIS and normal lipid profile. In pregnancy with android obesity patients had reduced plasma concentration of IL-10 and increased concentration of IL-6 which may impair the development of the placenta with increased risk of PT Neonatal complications and perinatal mortality were significantly higher in PPCOS with android obesity than PPCOS with gynoid obesity. (C) 2014 Production and hosting by Elsevier B.V. on behalf of Middle East Fertility Society.
引用
收藏
页码:293 / 302
页数:10
相关论文
共 50 条
  • [41] Placental steroidogenesis in pregnant women with polycystic ovary syndrome
    Maliqueo, Manuel
    Lara, Hernan E.
    Sanchez, Fernando
    Echiburu, Barbara
    Crisosto, Nicolas
    Sir-Petermann, Teresa
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2013, 166 (02) : 151 - 155
  • [42] Effect of orlistat on obese women with polycystic ovary syndrome
    Jiang Qi
    Shi Yuhua
    生物组学研究杂志(英文), 2018, (03) : 128 - 131
  • [43] Subclinical inflammation in obese women with polycystic ovary syndrome
    Elkholi, Dina
    Hammoudah, Sahar
    MIDDLE EAST FERTILITY SOCIETY JOURNAL, 2012, 17 (03) : 195 - 202
  • [44] Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes
    Palomba, Stefano
    Falbo, Angela
    Russo, Tiziana
    Tolino, Achille
    Orio, Francesco
    Zullo, Fulvio
    FERTILITY AND STERILITY, 2010, 94 (05) : 1805 - 1811
  • [45] Effects of Mixed of a Ketogenic Diet in Overweight and Obese Women with Polycystic Ovary Syndrome
    Cincione, Raffaele Ivan
    Losavio, Francesca
    Ciolli, Fabiana
    Valenzano, Anna
    Cibelli, Giuseppe
    Messina, Giovanni
    Polito, Rita
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (23)
  • [46] Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance
    Sepilian, V
    Nagamani, M
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (01): : 60 - 65
  • [47] Metabolic features of the reproductive phenotypes of polycystic ovary syndrome
    Moran, Lisa
    Teede, Helena
    HUMAN REPRODUCTION UPDATE, 2009, 15 (04) : 477 - 488
  • [48] The Role of Visceral Adiposity Index as Predictor of Metabolic Syndrome in Obese and Nonobese Women with Polycystic Ovary Syndrome
    de Medeiros, Sebastiao Freitas
    de Medeiros, Matheus Antonio Souto
    Barbosa, Bruna Barcelo
    Yamamoto, Marcia Marly Winck
    METABOLIC SYNDROME AND RELATED DISORDERS, 2021, 19 (01) : 18 - 25
  • [49] Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease
    Dereli, D
    Dereli, T
    Bayraktar, F
    Ozgen, AG
    Yilmaz, C
    ENDOCRINE JOURNAL, 2005, 52 (03) : 299 - 308
  • [50] Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome
    Apridonidze, T
    Essah, PA
    Iuorno, MJ
    Nestler, JE
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04): : 1929 - 1935